Mednow Launches New Virtual Diabetes Management Program in Partnership With Dexcom - Seite 2

“Our goal at Dexcom is to help those living with diabetes manage their condition proactively and efficiently, throughout every step of their journey,” said André Côté, General Manager of Dexcom Canada. “This includes how they access the system. We’ve learned that three-quarters of Dexcom users prefer to access their Dexcom rtCGM supplies from a pharmacy. In response, we’ve partnered with Mednow to provide users with a more convenient and coordinated experience, by making Dexcom G6 sensors and transmitters available through the pharmacy combined with enhanced virtual diabetes management support services.”

About Mednow:

Mednow is a healthcare technology company offering virtual access with a high-standard of care. Designed with accessibility and quality of care in mind, Mednow provides virtual pharmacy and telemedicine services as well as doctor home visits through an interdisciplinary approach to healthcare that is focused on the patient experience. Mednow’s services include free at-home delivery of medications, doctor consultations, a user-friendly interface for easy upload, transfer, and refill of prescriptions, access to healthcare professionals through an intuitive chat experience and the specialized PillSmart system that packages prescriptions in easy-to-use daily dose packs, each labeled with the date and time of the next dose. To learn more, follow Mednow on Facebook, Twitter, LinkedIn, and Instagram, or visit our website at www.mednow.ca/.

^* For a list of compatible devices, please visit www.dexcom.com/compatibility.

^† If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

References:

1. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
2. Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.
3. Roze S, Isitt J, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor Versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. Poster presentation presented at: 2020 Canadian Association for Population Therapeutics; October 27, 2020.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005403/en/

The Mednow Registered (A) Stock at the time of publication of the news with a raise of +2,08 % to 0,245USD on TSX Venture stock exchange (01. Februar 2023, 20:33 Uhr).